Dashboard
Manage Tickers

ORIC


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

openbench-and-oric-pharmaceuticals-partner-on-ai-driven-small-molecule-discovery-to-address-therapeutic-resistance-in-cancer
OpenBench And ORIC Pharmaceuticals Partner...
09/17/2024 16:05:11

wedbush-reiterates-outperform-on-oric-pharmaceuticals-maintains-20-price-target
Wedbush Reiterates Outperform on ORIC Phar...
09/10/2024 12:58:50

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

cantor-fitzgerald-reiterates-overweight-on-oric-pharmaceuticals
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 17:19:43

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

stifel-initiates-coverage-on-oric-pharmaceuticals-with-buy-rating-announces-price-target-of-20
Stifel Initiates Coverage On ORIC Pharmace...
09/06/2024 15:28:35

Stifel analyst Bradley Canino initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price...

hc-wainwright--co-reiterates-buy-on-oric-pharmaceuticals-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on ORIC...
08/14/2024 10:59:21

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...

wedbush-reiterates-outperform-on-oric-pharmaceuticals-maintains-20-price-target
Wedbush Reiterates Outperform on ORIC Phar...
08/13/2024 14:31:18

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

oppenheimer-maintains-outperform-on-oric-pharmaceuticals-lowers-price-target-to-15
Oppenheimer Maintains Outperform on ORIC P...
08/13/2024 10:06:50

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price targ...

oric-pharmaceuticals-q2-eps-045-misses-041-estimate
ORIC Pharmaceuticals Q2 EPS $(0.45) Misses...
08/12/2024 20:18:43

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate o...

wedbush-reiterates-outperform-on-oric-pharmaceuticals-maintains-20-price-target
Wedbush Reiterates Outperform on ORIC Phar...
07/17/2024 13:17:41

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

hc-wainwright--co-reiterates-buy-on-oric-pharmaceuticals-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on ORIC...
07/17/2024 10:32:32

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...

Core News & Articles
ORIC Pharmaceuticals Says Entered Into Cli...
07/16/2024 21:01:15

oppenheimer-maintains-outperform-on-oric-pharmaceuticals-maintains-17-price-target
Oppenheimer Maintains Outperform on ORIC P...
07/10/2024 17:20:45

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $17 price t...

cantor-fitzgerald-reiterates-overweight-on-oric-pharmaceuticals
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:43:45

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

cantor-fitzgerald-reiterates-overweight-on-oric-pharmaceuticals
Cantor Fitzgerald Reiterates Overweight on...
05/28/2024 13:13:40

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

citigroup-maintains-buy-on-oric-pharmaceuticals-lowers-price-target-to-14
Citigroup Maintains Buy on ORIC Pharmaceut...
05/07/2024 17:37:19

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from...

oric-pharmaceuticals-q1-eps-037-beats-051-estimate
ORIC Pharmaceuticals Q1 EPS $(0.37) Beats ...
05/06/2024 20:12:25

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of ...

oric-pharmaceuticals-announces-first-patients-dosed-across-three-expansion-cohorts-in-phase-1b-trial-of-oric-114-in-patients-with-mutated-nsclc
ORIC Pharmaceuticals Announces First Patie...
04/15/2024 20:16:07

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon ...

oric-pharmaceuticals-presents-preclinical-data-on-two-programs-at-the-2024-aacr-annual-meeting
ORIC Pharmaceuticals Presents Preclinical ...
04/08/2024 12:15:21

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinic...

jp-morgan-maintains-overweight-on-oric-pharmaceuticals-lowers-price-target-to-18
JP Morgan Maintains Overweight on ORIC Pha...
03/27/2024 14:40:45

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...

micron-to-rally-around-134-here-are-10-top-analyst-forecasts-for-thursday
Micron To Rally Around 134%? Here Are 10 T...
03/21/2024 13:15:39

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION